265 related articles for article (PubMed ID: 26253290)
1. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
Pan HY; Pan HY; Chen L; Yang DH; Huang HJ; Tong YX; Chen CR; Yan J
Clin Microbiol Infect; 2015 Dec; 21(12):1123.e1-9. PubMed ID: 26253290
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
[TBL] [Abstract][Full Text] [Related]
4. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
[TBL] [Abstract][Full Text] [Related]
5. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients.
Chen DB; Chen YM; Liu J; Xie DY; Lu CR; Huang ZL; Zhu RH; Gao ZL
J Clin Virol; 2014 Jan; 59(1):50-4. PubMed ID: 24300414
[TBL] [Abstract][Full Text] [Related]
6. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.
Yao CC; Lee CM; Hung CH; Wang JH; Hu TH; Lu SN; Changchien CS; Hsu MC; Chen CH
J Gastroenterol Hepatol; 2015 May; 30(5):918-24. PubMed ID: 25532588
[TBL] [Abstract][Full Text] [Related]
7. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
[TBL] [Abstract][Full Text] [Related]
8. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
Liang Y; Jiang J; Su M; Liu Z; Guo W; Huang X; Xie R; Ge S; Hu J; Jiang Z; Zhu M; Wong VW; Chan HL
Aliment Pharmacol Ther; 2011 Aug; 34(3):344-52. PubMed ID: 21671967
[TBL] [Abstract][Full Text] [Related]
9. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
Chen CH; Lu SN; Hung CH; Wang JH; Hu TH; Changchien CS; Lee CM
J Hepatol; 2014 Sep; 61(3):515-22. PubMed ID: 24798617
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
12. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
[TBL] [Abstract][Full Text] [Related]
14. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
15. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
[TBL] [Abstract][Full Text] [Related]
16. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
[TBL] [Abstract][Full Text] [Related]
17. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
Alexander G; Baba CS; Chetri K; Negi TS; Choudhuri G
BMC Gastroenterol; 2005 Sep; 5():29. PubMed ID: 16164746
[TBL] [Abstract][Full Text] [Related]
18. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
19. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
